ArticleClinical Medicine Insights. Oncology2020

Efficacy of Docetaxel Plus Ramucirumab as Palliative Third-Line Therapy Following Second-Line Immune-Checkpoint-Inhibitor Treatment in Patients With Non-Small-Cell Lung Cancer Stage IV.

Wolfgang M Brueckl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.